R&D channel feed

As­traZeneca's block­buster Farx­i­ga se­cures land­mark ap­proval in heart fail­ure pa­tients, re­gard­less of whether they have di­a­betes

6 years ago
FDA+

J&J R&D ex­ec Na­jat Khan — and da­ta sci­ence — are get­ting an el­e­vat­ed role at the phar­ma gi­ant

6 years ago
People
AI

A risky bet on a long-de­layed CAR-T drug now faces a do-or-die dead­line — where any slip can kill a $9 CVR

6 years ago
FDA+

Roche flash­es new 16-week bis­pe­cif­ic AMD da­ta, set­ting eyes on pair of PhI­II tri­als

6 years ago

Af­ter big 2016 set­back, field of mi­cro­bio­me-based drugs gets in­jec­tion of promise with pos­i­tive sig­nal from Re­bi­otix piv­otal study

6 years ago

Oust­ed BAR­DA chief Rick Bright blasts HHS of­fi­cial for a long record of im­prop­er in­ter­fer­ence that pre­ced­ed the pan­dem­ic

6 years ago
People

Ake­bia touts da­ta for two PhI­II stud­ies, set­ting up show­down with As­traZeneca, Fi­bro­Gen

6 years ago

Two years af­ter U2 dis­ap­point­ment, TG Ther­a­peu­tics wins back in­vestors with PFS win — set­ting the stage for NDA

6 years ago

A UCSD cen­ter that's been fa­cil­i­tat­ing Covid-19 clin­i­cal re­search gets $55M from NIH to boost trans­la­tion­al work

6 years ago
Discovery

Prax­is Pre­ci­sion Med­i­cines launch­es with $100M and bold sights on long-eva­sive neu­ro­log­i­cal dis­or­ders

6 years ago
Financing
Startups

Bat­tling low ex­pec­ta­tions and go­liath ri­vals, Re­gen­eron/Sanofi add pos­i­tive Lib­tayo da­ta in pur­suit of block­buster sta­tus

6 years ago
FDA+

Al­ny­lam, Sarep­ta jump in­to Covid-19 game, as pan­dem­ic rekin­dles an­tivi­ral hopes of RNA-tar­get­ing tech­nol­o­gy

6 years ago
Coronavirus
In Focus

Bio­Marin broad­ens its gene ther­a­py hori­zons with a new R&D al­liance in rare car­dio cas­es

6 years ago
Deals
Cell/Gene Tx

Newron's Mer­ck KGaA-in li­censed com­pound fails Rett Syn­drome study, shares wilt

6 years ago

FDA cheers on Gilead­'s remde­sivir with a snap emer­gency OK, giv­ing bio­phar­ma a shot at re­demp­tion

6 years ago
FDA+
Coronavirus

Tick sali­va-de­rived drug shows promise in mid-stage rare skin dis­ease study

6 years ago

Bris­tol My­ers Squibb gets pri­or­i­ty re­view for AML drug as list of po­ten­tial Cel­gene hits length­ens

6 years ago
FDA+

Com­mer­cial strat­e­gy for Gilead­'s Covid-19 drug-to-be remde­sivir re­mains opaque, as chief O'­Day em­pha­sizes re­spon­si­bil­i­ty

6 years ago
Pharma
FDA+

10X: Mod­er­na cre­ates a bil­lion-dose vac­cine pact in a fren­zied race to beat Covid-19 — glob­al­ly

6 years ago
Coronavirus

Af­ter NIH tri­al, EMA be­gins rolling re­view for remde­sivir, set­ting up po­ten­tial au­tho­riza­tions in US and Eu­rope

6 years ago
FDA+
Coronavirus

Con­gres­sion­al watch­dog ad­vis­es HHS to im­ple­ment 'post-mar­ket­ing' in­cen­tives to ad­dress dwin­dling an­tibi­ot­ic de­vel­op­ment ef­forts

6 years ago

Da­ta on Gilead­'s an­tivi­ral bring hope for first Covid-19 drug ap­proval

6 years ago
Coronavirus

No­var­tis spin­out resTOR­bio re­verse merges with T cell biotech af­ter big PhI­II fail­ure

6 years ago
Cell/Gene Tx

Gilead — Piv­otal Covid-19 study of remde­sivir ‘met its pri­ma­ry end­point,' is emer­gency au­tho­riza­tion next?

6 years ago
Coronavirus
First page Previous page 203204205206207208209 Next page Last page
A service from the Financial Times